美国食品药品监督管理局批准Crenessity用于治疗先天性上腺增生, FDA approves Crenessity for treating congenital adrenal hyperplasia, a first in 70 years.

美国食品和药物管理局批准了神经生科学公司的Crenessity用于治疗成人和4岁儿童的先天性上腺增生 (CAH). The FDA has approved Neurocrine Biosciences' Crenessity for treating congenital adrenal hyperplasia (CAH) in adults and children as young as four. 这种70年来首次用于CAH的新疗法减少了上腺的雄激素产生, This first new treatment for CAH in 70 years reduces adrenal androgen production, allowing lower doses of glucocorticoids. 常见副作用包括疲劳、头痛和成人头晕、头痛、腹痛和儿童疲劳。 Common side effects include fatigue, headache, and dizziness in adults, and headache, abdominal pain, and fatigue in children. 克雷尼西蒂将在一个星期内通过专业药店出售. Crenessity will be available through a specialty pharmacy in about a week.